Neurocrine replaces CMO Keswani with former chief Roberts amid pipeline expansion

Neurocrine is a commercial-stage neuroscience and endocrine biotech, led by INGREZZA and CRENESSITY while expanding a mid- to late-stage pipeline and integrating the Soleno acquisition. The abrupt CMO change is a real leadership disruption, not routine succession. The company says Sanjay Keswani’s service ended by mutual agreement on September 25, only about 15 months after he took over the role, before Eiry Roberts was appointed effective September 28. 〔0〕

Roberts’ return cushions the operational risk. She previously served as Neurocrine’s CMO for seven years before moving into a strategic-advisor role, so the company is restoring an experienced internal leader rather than searching externally. That continuity matters while Neurocrine is advancing multiple clinical programs and broadening its commercial portfolio. The signal is still mixed because the filing gives no reason for Keswani’s departure. It also commits to severance for him and a new compensation package for Roberts, including an $825,000 salary and approximately $1.25 million of target equity grants, creating incremental cost but not a material capital event. 〔1〕

Bottom line: This is a meaningful management reset in a key R&D role, but the return of a proven former CMO limits the risk of a prolonged transition. The business story is therefore more complicated than impaired: disruption is evident, while continuity is preserved.